To advance standardized immunotherapy diagnosis and treatment while strengthening multidisciplinary collaboration, the "2025 Multidisciplinary Alliance Immunology Academy Clinical Translational Medicine Symposium" hosted by Chengdu High-Tech Medical Association was successfully held in Chengdu on March 28,2025.
The event adopted a hybrid offline-online format, gathering authoritative experts, scholars, and industry representatives from global oncology fields to explore new pathways for clinical translation of immunotherapy and multidisciplinary treatment (MDT).
As a groundbreaking therapeutic approach in recent years, tumor immunotherapy has brought renewed hope for survival to cancer patients, yet its unique challenges in adverse reaction management have become increasingly prominent.
This symposium focused on core topics including mechanistic studies of immunotherapy adverse reactions, clinical management strategies, and multidisciplinary collaboration models, sharing cutting-edge research findings and case study experiences.
Immunotherapy for cancer has significantly improved the treatment of malignant tumors.
However, its side effects differ from those of traditional chemotherapy and targeted therapy, characterized by a wide range of involvement, high incidence, and early misdiagnosis or missed diagnosis. In severe cases, these side effects can be life-threatening, necessitating the formation of multidisciplinary teams for standardized diagnosis and treatment.
This conference is a crucial opportunity to promote the standardization of immunotherapy in China. It brings together medical institutions, research units, and related enterprises from across the country, using methods such as academic presentations, roundtable discussions, and case studies to deepen the integration of clinical and translational medicine, ultimately benefiting a large number of cancer patients.
